March 2011
Worldwide Biotech;Mar2011, Vol. 23 Issue 3, p1
Trade Publication
The article provides information on a drug developed by Gentium S.p.A. in Italy, called defibrotide, for the prevention and treatment of veno-occlusive disease (VOD), a life threatening condition of the liver that occur when a patient undergoes stem cell transplant. A detailed description of VOD is provided. In the research study led by Gentium Scientific director Massimo Iacobelli, the drug is reported to have no side effects on rats and healthy human volunteers, while pregnant rats showed maternal toxicity and intrauterine development of the progeny.


Related Articles

  • Gentium Voluntarily Pulls NDA For Defibrotide; Shares Tumble. Powers, Marie // BioWorld Today;8/19/2011, Vol. 22 Issue 161, p1 

    This article reports on the voluntary withdrawal by Gentium SpA of its new drug application (NDA) for defibrotide. The company took the move 36 hours after receiving a letter from the Food and Drug Administration ( FDA) which cited a number of issues regarding the NDA for defibrotide. The drug...

  • Viral infections in paediatric patients receiving conventional cancer chemotherapy. Simon, A.; Schildgen, O.; Schuster, F. // Archives of Disease in Childhood;Oct2008, Vol. 93 Issue 10, p880 

    In severely immunocompromised patients, the diagnosis of viral infections relies on PCR/RT-PCR based methods. The availability of these modern diagnostic tools facilitates timely diagnosis and contributes to our increasing knowledge of the epidemiology and clinical spectrum of common and...

  • Pharmacogenetics of Gemtuzumab-Associated Hepatic Sinusoidal Occlusion Syndrome after Hematopoietic Stem Cell Transplant. Aplenc, Richard; Vachani, Anil; Han, Peggy; Glatfelter, Wendy; Sievers, Eric L. // Acta Haematologica;Dec2003, Vol. 110 Issue 4, p207 

    Presents a study that investigated the pharmacogenetics of Gemtuzumab-associated hepatic sinusoidal occlusion syndrome (SOS) after hematopoietic stem cell transplant (HSCT). Variable risk of SOS development in patients exposed to gemtuzumab after HSCT; Analysis of reactive oxygen species...

  • Antimicrobial Peptides as Anti-Infectives against Staphylococcus epidermidis. Agarwal, Sangya; Sharma, Garima; Dang, Shweta; Gupta, Sanjay; Gabrani, Reema // Medical Principles & Practice;Jun2016, Vol. 25 Issue 4, p301 

    Staphylococcus epidermidis has emerged as the main causative agent for graft-related and nosocomial infections. Rampant use of antibiotics and biofilm formed by the organism results in poor penetration of the drug and further aggravates the antibiotic resistance, emphasizing an urgent need to...

  • Gentium Announces NDA Submission for Defibrotide.  // Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p2 

    The article reports on a new drug application (NDA) submitted by Gentium SpA to the U.S. Food and Drug Administration (FDA) for Defibrotide for the treatment of hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem-cell transplantation (HSCT). The drug has allegedly been...

  • Concerns Raised on Gentium's Phase III Study.  // Bioworld Week;6/16/2008, Vol. 16 Issue 24, p2 

    The article reports on the suggestion of an independent data safety monitoring board (DSMB) for Gentium SpA to confirm the criteria for a Phase III trial of its defibrotide in the U.S. Gentium is asked to confirm the criteria used to select historical control patients for the trial of its...

  • Gentium Shares Take Beating on Concerns About Study. Turner, Tiffany // BioWorld Today;6/9/2008, Vol. 19 Issue 111, p1 

    The article reports on the decrease in stock of Gentium SpA in June 2009 on news that an independent data safety monitoring board (DSMB) recommended that the company confirm the criteria used to select historical control patients for a Phase III trial of its lead product, defibrotide, in...

  • Gentium Shares Falling as Defibrotide Faces Delay Again. Sheridan, Cormac // BioWorld Today;2/25/2013, Vol. 24 Issue 36, p1 

    The article reports that share prices for Gentium SpA has fallen 20 percent due to the delayed approval of the drug defibrotide. The drug is developed for the treatment and prevention of hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem cell transplant. Preliminary...

  • Association of Busulfan and Cyclophosphamide Conditioning with Sleep Disorders after Hematopoietic Stem Cell Transplantation. Faulhaber, Gustavo A. M.; Furlanetto, Tania W.; Astigarraga, Claudia C.; Filho, Humberto Luiz Moser; Paludo, Angela Paula; Silla, Lucia M. R. // Acta Haematologica;Oct2010, Vol. 124 Issue 2, p125 

    New indications and conditioning regimens for hematopoietic stem cell transplantation (HSCT) have emerged in the last 10 years. Previous studies have shown the association of HSCT with late effects such as sleep disorders. The aim of this study was to determine the prevalence and factors...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics